Table 1 Baseline characteristics of the study cohort

Number of patients

214

Age (years)

41.4 ± 12.6

Sex (male, %)

66.4%

Mean arterial pressure (mmHg)

99 ± 15

Serum creatinine (mg/dL)

2.02 ± 1.57

eGFR (ml/min/1.73m²)

55.2 ± 31.5

CKD stage (%)

• G1

15.8%

• G2

24.8%

• G3

34.1%

• G4

19.2%

• G5

6.1%

Albumin (g/dL)

4.07 ± 0.63

Serum IgA (mg/dL)

351 ± 153

Increased serum IgA (% pf pts.)

27.9%

Serum C3 (mg/dL)

116 ± 24

Decreased serum C3 (% of pts.)

12.9%

IgA/C3 ratio

3.18 ± 1.62

Hematuria (cells/µL)

35 (14–84)

Hematuria (% of pts)

• Absent

37.2%

• Mild

28%

• Moderate

15.5%

• Severe

19.3%

24-h proteinuria (g/24 h)

1.5 (0.8–3.25)

24-h proteinuria (% of pts)

• Proteinuria < 0.75 g/24 h (%)

22.9%

• Proteinuria 0.75–3.5 g/24 h (%)

54.2%

• Proteinuria > 3.5 g/24 h (%)

22.9%

Treatment

• RAAS inhibitors (%)

88%

• Corticosteroids monotherapy (%)

46.2%

• Corticosteroids ± other immunosuppressive agent (%)

25.5%

Outcome

• Doubling of serum creatinine (%)

18.2%

• ESRD (%)

24.8%

• Combined endpoint (%)

29%

Follow-up (months)

49.1 (17.3–86.2)